Trial Profile
A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia [CLL]
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2006
Price :
$35
*
At a glance
- Drugs Oblimersen (Primary) ; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Sponsors Genta (CEASED)
- 31 Jul 2006 New trial record.